Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Fears 'Real' Biosimilar Competition Says Russia's Biocad

Executive Summary

Russia's Biocad has lashed out against Roche after being at the receiving end of what it claims are the Swiss multinational's 'scare tactics' against biosimilar competition in Sri Lanka. Biocad says it intends to pursue damages in the Sri Lankan case while Roche, which is standing its ground, has moved the Supreme Court in the island nation.

You may also be interested in...

Indian Avastin Biosimilar Arrives Amid Roche's Charges

Reliance Life Sciences has introduced its biosimilar version of Roche's anticancer, Avastin (bevacizumab), on the Indian market but the Swiss multinational has claimed it is unconvinced of the rigor involved in the regulatory scrutiny of the product.

Indian Herceptin Biosimilars Case Simmers

The hotly contested case concerning biosimilar versions of Roche's Herceptin (trastuzumab) witnessed a seesaw shift after a division bench of the Delhi High Court held that the status prevailing prior to a stinging April 25 order against Biocon Ltd. and Mylan NV will continue to operate.

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts